Piper Sandler analyst Adam Maeder notes that Nevro announced preliminary Q4 revenue that came in modestly above consensus and also issued 2023 guidance that brackets the Street. However, he views the company’s guidance "as a touch lofty" and more broadly still has concerns about visibility into core spinal cord stimulation market growth amid a potentially more competitive SCS market, said Maeder, who keeps an Underweight rating and $38 price target on Nevro shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVRO:
- Nevro CEO Keith Grossman to retire in 2023
- Nevro sees FY23 revenue $445M-$455M, consensus $451.3M
- Nevro reports preliminary Q4 revenue $113.8M, consensus $112.55M
- Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance
- Nevro downgraded to Underweight from Neutral at Piper Sandler
